Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Client expense: $53,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

H.R. 2033/S.1107 - Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011; Psoriasis Data Collection.

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE

H.R. 2033/S.1107 - Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011; Psoriasis Data Collection.

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Access to care for people with psoriasis and psoriatic arthritis: H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 H.R.4209: Patients' Access to Treatments Act of 2012

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

Client expense: $80,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

H.R. 2033/S.1107 - Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011; Psoriasis Data Collection.

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE

S. 296 / H.R. 2245 Preserving Access to Life Saving Medications Act of 2011; S. 660 PATIENTS Act of 2011; S. 668 Health Care Bureaucrats Elimination Act; S. 1107 / H.R. 2033 Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011; H.R. 5 Help Efficient, Accessible, Low Cost, Timely Healthcare Act; S. 1699 Prescription Drug Cost Reduction Act

Client expense: $70,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

S. 296 / H.R. 2245 Preserving Access to Life Saving Medications Act of 2011; S. 660 PATIENTS Act of 2011; S. 668 Health Care Bureaucrats Elimination Act; S. 1107 / H.R. 2033 Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011; H.R. 5 Help Efficient, Accessible, Low Cost, Timely Healthcare Act; S. 1699 Prescription Drug Cost Reduction Act

Client expense: $70,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SEC. 3. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION. (a) In General- The Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, is authorized to undertake psoriasis and psoriatic arthritis data collection efforts, including incorporating questions into public health surveys, questionnaires, and other databases in existence as of the date of the enactment of this Act to collect information, with respect to psoriasis and psoriatic arthritis, regarding-- (1) the prevalence of psoriasis and psoriatic arthritis in the United States; (2) the age of onset; (3) health-related quality of life; (4) health care utilization; (5) burden of such disease (such as with respect to employment); (6) direct and indirect costs; (7) health disparities, including with respect to age, gender, race, and ethnicity; and (8) comorbidities and the natural history of such disease. Such data collection efforts may include the consideration and development of a patient registry, which would include individuals of all ages. (b) Authorization of Appropriations- To carry out subsection (a), there are authorized to be appropriated $1,500,000 for each of fiscal years 2012 through 2017. SEC. 4. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS. It is the sense of the Congress that-- (1) the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases; (2) the nonprofit and private sector psoriasis research communities are to be commended for planning a multidisciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions; (3) the National Institutes of Health is encouraged to continue to work with the organizations and private sector stakeholders who convene the multidisciplinary scientific meeting to discuss future directions of psoriasis and comorbid research; (4) the nonprofit and private sector meeting conveners should disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from the National Institutes of Health and other relevant Federal agencies; and (5) utilizing the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research, the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases and other institutes and centers of the National Institutes of Health, is encouraged to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

Client expense: $97,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Monitor implementation of the Patient Protection and Affordable Care Act. (P.L. 111-148) S. 600, Use It or Lose It Act of 2011. S. 660, PATIENTS Act of 2011. S. 668, Health Care Bureaucrats Elimination Act. S. 1042, Medicare Patient Empowerment Act. H.R. 1700, Medicare Patient Empowerment Act. S. 1107, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011. H.R. 2033, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011. S. 1599, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. H.R. 3070, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. S. 1699, Prescription Drug Cost Reduction Act. S. 1720, Jobs Through Growth Act. H.R. 3400, Jobs Through Growth Act. H.J. Res 79, Continuing Appropriations Resolution, 2012. H.R. 452, Medicare Decisions Accountability Act of 2011. H.R. 1173, Fiscal Responsibility and Retirement Security Act of 2011. H.R. 1744, American Job Protection Act. H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012 H.R. 2363, Health Care OverUse Reform Today Act (HealthCOURT Act) of 2011. H.R. 2576, To amend the Internal Revenue Code of 1986 to modify the calculation of modified adjusted gross income for purposes of determining eligibility for certain healthcare-related programs. H.R. 3630, Temporary Payroll Tax Cut Continuation Act of 2011. Monitor federal issues and legislation associated with health care policy.

Client expense: Not reported · Firm income: $50,000

H.R. 2033/S.1107 - Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011; Psoriasis Data Collection.

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, White House Office

S. 296 / H.R. 2245 Preserving Access to Life Saving Medications Act of 2011; S. 1107 / H.R. 2033 Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011; S. 218 / H.R. 5 Help Efficient, Accessible, Low-Cost, Timely Healthcare Act (HEALTH) of 2011; S. 668 Health Care Bureaucrats Elimination Act

Client expense: $115,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Monitor implementation of the Patient Protection and Affordable Care Act. (P.L. 111-148) S.391 Recovering Excessive Stimulus Expenditures for Taxpayers Act. S. 218 Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011. S. 296, Preserving Access to Life-Saving Medications Act. H.R. 2245, Preserving Access to Life-Saving Medications Act of 2011. S. 365, Budget Control Act. S. 600, Use It or Lose It Act of 2011. S. 660, PATIENTS Act of 2011. S. 668, Health Care Bureaucrats Elimination Act. S. 1031, Medicaid Improvement and State Empowerment Act. S. 1042, Medicare Patient Empowerment Act. H.R. 1700, Medicare Patient Empowerment Act. S. 1096, Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011. H.R. 2020, Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011. S. 1107, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011. H.R. 2033, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011. S. 1275, Social Security Number Protection Act of 2011. S. 1395, WAIVE Act. S. 1599, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. H.R. 3070, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012. H. J. Res 79, Continuing Appropriations Resolution, 2012. H.R. 2 Repealing the Job-Killing Health Care Law Act. H.R. 5 Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011. H.R. 452, Medicare Decisions Accountability Act of 2011. H.R. 1216, To amend the Public Health Service Act to convert funding for graduate medical education in qualified teaching health centers from direct appropriations to an authorization of appropriations. H.R. 1744, American Job Protection Act. H.R. 2017, Continuing Appropriations Act, 2012. H.R. 2077, MLR Repeal Act of 2011. H.R. 2206, Auto Enroll Repeal Act. H.R. 2224, Improving Physician Access in Teaching Hospitals (PATH) Act of 2011. H.R. 2363, Health Care OverUse Reform Today Act (HealthCOURT Act) of 2011. Monitor federal issues and legislation associated with health care policy.

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

Client expense: $60,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

H.R. 2033/S.1107 - Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011; Psoriasis Data Collection.

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, White House Office

Monitor implementation of the Patient Protection and Affordable Care Act. (P.L. 111-148) S.391 Recovering Excessive Stimulus Expenditures for Taxpayers Act. S. 218 Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011. S. 600, Use It or Lose It Act of 2011. S. 660, PATIENTS Act of 2011. S. 668, Health Care Bureaucrats Elimination Act. S. 1031, Medicaid Improvement and State Empowerment Act. S. 1107, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011. H.R. 2033, Psoriasis and Psoriatic Arthritis Research, Cure, and Care Act of 2011. S. 1275, Social Security Number Protection Act of 2011. H.R. 2 Repealing the Job-Killing Health Care Law Act. H.R. 5 Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2011. H.R. 452, Medicare Decisions Accountability Act of 2011. H.R. 1216, To amend the Public Health Service Act to convert funding for graduate medical education in qualified teaching health centers from direct appropriations to an authorization of appropriations. H.R. 1700, Medicare Patient Empowerment Act. H.R. 1744, American Job Protection Act. H.R. 2020, Preservation of Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2011. H.R. 2077, MLR Repeal Act of 2011. H.R. 2206, Auto Enroll Repeal Act. H.R. 2224, Improving Physician Access in Teaching Hospitals (PATH) Act of 2011. H.R. 2363, Health Care OverUse Reform Today Act (HealthCOURT Act) of 2011. Monitor federal issues and legislation associated with health care policy.

Client expense: Not reported · Firm income: $50,000

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

Client expense: $150,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Access to care for people with psoriasis and psoriatic arthritis H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011

Client expense: $150,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

H.R.2033: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 S.1107: The Psoriasis and Psoriatic Arthritis Research, Cure and Care Act of 2011 SECTION 4. NATIONAL PSORIASIS AND PSORIATIC ARTHRITIS DATA COLLECTION Authorizes the Centers for Disease Control and Prevention (CDC) to undertake psoriasis and psoriatic arthritis data collection efforts including: incorporating questions into existing public health surveys, questionnaires and other databases to collect information regarding prevalence in the United States, age of onset, health-related quality of life, health care utilization, burden of disease (employment, work, etc.), direct and indirect costs, health disparities (age, gender, racial, ethnic), comorbidities and natural history of disease. These efforts may include the consideration and development of a patient registry, which would include individuals of all ages. SECTION 5. SENSE OF CONGRESS FOR COLLABORATIVE INTERDISCIPLINARY RESEARCH ON PSORIASIS AND PSORIATIC ARTHRITIS AND COMORBID CONDITIONS Non-binding language that: Recognizes that the psoriasis research community has made significant strides in proving the seriousness of psoriasis as an autoimmune disease and in advancing the identification of commonalities between psoriasis and other diseases. Commends the non-profit and private sector psoriasis research communities for planning a multi-disciplinary scientific meeting in 2012 to discuss future directions of psoriasis and comorbid research, identify initiatives necessary to fill any gaps, leverage public and private investments in psoriasis research, and facilitate progress in interdisciplinary research related to psoriasis and its comorbid conditions. Encourages the National Institutes of Health (NIH) to continue to work with the organizations and private sector stakeholders who convene the multi-disciplinary scientific meeting to discuss future directions of psoriasis and comorbid research. Suggests that the non-profit and private sector meeting conveners disseminate to the public, Congress, and other relevant public and private policymaking and research entities a report that includes findings from the scientific meeting and suggestions regarding next steps, including recommendations from NIH and other relevant federal agencies. Encourages the Secretary of the Department of Health and Human Services (HHS), acting through the Director of the NIH, and in conjunction with the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) and other NIH institutes and centers, to utilize the information produced by the scientific meeting regarding future directions of psoriasis and comorbid research and to explore the development of a virtual Center of Excellence for Collaborative Discovery in Psoriasis and Comorbid Research or some other mechanism through which public and private sector findings regarding psoriasis and its comorbid conditions can be regularly shared and leveraged.